UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on HeartWare International
In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on HeartWare International (NASDAQ: HTWR), and raised its price target from $101.00 to $110.00.
Canaccord noted, “HTWR handily beat our Q2E, expanded its #1 LVAD share position OUS, and has several upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device). We continue to estimate HTWR will replicate its strong OUS performance in the US subsequent to FDA BTT approval (SeptE) and DT approval (late ‘14E). HTWR remains one of our top picks. We raise our PT to $110 and reiterate our BUY rating.”
HeartWare International closed on Tuesday at $86.88.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tags: Canaccord GenuityAdvertisement